Salarius Pharmaceuticals Files Proxy Materials
Ticker: DCOY · Form: DEFA14A · Filed: Nov 1, 2024 · CIK: 1615219
Sentiment: neutral
Topics: proxy-filing, shareholder-meeting, governance
TL;DR
Salarius Pharma dropped proxy docs, shareholders vote soon.
AI Summary
Salarius Pharmaceuticals, Inc. filed a Definitive Additional Materials proxy statement on November 1, 2024. This filing is related to their annual meeting and likely contains information about shareholder proposals, director elections, and executive compensation. The company is incorporated in Delaware and headquartered in Houston, Texas.
Why It Matters
This filing provides shareholders with crucial information to make informed decisions regarding company governance and voting at the upcoming annual meeting.
Risk Assessment
Risk Level: low — This is a routine proxy filing and does not inherently introduce new financial risks.
Key Players & Entities
- Salarius Pharmaceuticals, Inc. (company) — Registrant
- 20241101 (date) — Filing Date
- DEFA14A (document_type) — Filing Type
- Houston, TX (location) — Company Headquarters
FAQ
What type of filing is this DEFA14A for Salarius Pharmaceuticals, Inc.?
This filing is classified as 'Definitive Additional Materials' under Schedule 14A, indicating it provides supplementary information to shareholders.
When was this DEFA14A filing submitted to the SEC?
The filing was submitted on November 1, 2024.
Where is Salarius Pharmaceuticals, Inc. headquartered?
Salarius Pharmaceuticals, Inc. is headquartered in Houston, Texas.
What is the Standard Industrial Classification (SIC) code for Salarius Pharmaceuticals, Inc.?
The SIC code for Salarius Pharmaceuticals, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
Does this filing require a fee payment?
According to the filing, no fee was required for this submission.
Filing Stats: 140 words · 1 min read · ~1 pages · Grade level 12.3 · Accepted 2024-11-01 17:05:56
Filing Documents
- salarius-defa14a2023proxy.htm (DEFA14A) — 16KB
- image.jpg (GRAPHIC) — 142KB
- image1.jpg (GRAPHIC) — 92KB
- 0001615219-24-000086.txt ( ) — 339KB
From the Filing
Document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant Filed by a Party other than the Registrant Check the appropriate box Preliminary Proxy Statement Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) Definitive Proxy Statement Definitive Additional Materials Soliciting Material Pursuant to 240.14a-12 Salarius Pharmaceuticals, Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check the appropriate box) No fee required. Fee paid previously with preliminary materials. Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Amount Previously Paid (2) Form, Schedule or Registration Statement No. (3) Filing Party (4) Date Filed